Prolonged islet allograft survival in diabetic nod mice by targeting CD45RB and CD154

Diabetes

Volumn 52, Issue 4, 2003, Pages 957-964

  Molano, R Damaris ^a   Pileggi, Antonello ^a   Berney, Thierry ^a   Poggioli, Raffaella ^a   Zahr, Elsie ^a   Oliver, Robert ^a   Ricordi, Camillo ^a   Rothstein, David M ^b   Basadonna, Giacomo P ^b   Inverardi, Luca ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD45 ANTIGEN; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY CD45; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MIXED LYMPHOCYTE REACTION; MOUSE; MOUSE STRAIN; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ANTIGENS, CD45; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GRAFT SURVIVAL; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-7; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; RNA, MESSENGER; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037381446     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.4.957     Document Type: Article

References (36)

1. Alejandro R, Lehmann R, Ricordi C, Kenyon NS, Angelico MC, Burke G, Esquenazi V, Nery J, Betancourt AE, Kong SS, Miller J, Mintz DH: Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes 46:1983-1989, 1997
2. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230-238, 2000
3. Ryan EA, Lakey JR, Rajotte RV, Korbutt GS, Kin T, Imes S, Rabinovitch A, Elliott JF, Bigam D, Kneteman NM, Warnock GL, Larsen I, Shapiro AM: Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 50:710-719, 2001
4. Ryan EA, Lakey JR, Paty BW, Imes S, Korbutt GS, Kneteman NM, Bigam D, Rajotte RV, Shapiro AMJ: Successful islet transplantation. Continued insulin reserve provides long-term glycemic control. Diabetes 51:2148-2157, 2002
5. Pileggi A, Ricordi C, Alessiani M, Inverardi L: Factors influencing islet of Langerhans graft function and monitoring. Clin Chim Acta 310:3-16, 2001
6. Lazarovits AI, Poppema S, Zhang Z, Khandaker M, Le Feuvre CE, Singhal SK, Garcia BM, Ogasa N, Jevnikar AM, White MH, Singh G, Stiller CR, Zhong RZ: Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature 380:717-720, 1996
7. Davies JD, O'Connor E, Hall D, Krahl T, Trotter J, Sarvetnick N: CD4(+) CD45RB low-density cells from untreated mice prevent acute allograft rejection. J Immunol 163:5353-5357, 1999
8. Basadonna GP, Auersvald L, Khuong CQ, Zheng XX, Kashio N, Zekzer D, Minozzo M, Qian H, Visser L, Diepstra A, Lazarovits AI, Poppema S, Strom TB, Rothstein DM: Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy. Proc Natl Acad Sci U S A 95:3821-3826, 1998
9. Auersvald LA, Rothstein DM, Oliveira SC, Khuong CQ, Onodera H, Lazarovits AI, Basadonna GP: Indefinite islet allograft survival in mice after a short course of treatment with anti-CD45 monoclonal antibodies. Transplantation 63:1355-1358, 1997
10. Fecteau S, Basadonna GP, Freitas A, Ariyan C, Sayegh MH, Rothstein DM: CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nat Immunol 2:58-63, 2001
11. Rothstein DM, Livak MF, Kishimoto K, Ariyan C, Qian HY, Fecteau S, Sho M, Deng S, Zheng XX, Sayegh MH, Basadonna GP: Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol 166:322-329, 2001
12. Yamada A, Sayegh MH: The CD154-CD40 costimulatory pathway in transplantation. Transplantation 73:S36-S39, 2002
13. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, Hong X, Thomas D, Fechner JH, Knechtle SJ: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 94:8789-8794, 1997
14. Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fenchner JH, Germond RL, Kampen RL, Patterson NB, Swanson SJ, Tadaki DK, TenHoor CN, White L, Knechtle SJ, Harlan DM: Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in non-human primates. Nat Med 5:686-693, 1999
15. Kenyon NS, Chatzipetrou M, Masetti M, Ranuncoli A, Oliveira M, Wagner JL, Kirk AD, Harlan DM, Burkly LC, Ricordi C: Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A 96:8132-8137, 1999
16. Kenyon NS, Fernandez LA, Lehmann R, Masetti M, Ranuncoli A, Chatzipetrou M, Iaria G, Han D, Wagner JL, Ruiz P, Berho M, Inverardi L, Alejandro R, Mintz DH, Kirk AD, Harlan DM, Burkly LC, Ricordi C: Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 48:1473-1481, 1999
17. Early GS, Zhao W, Burns CM: Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 157:3159-3164, 1996
18. Durie FH, Rava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ: Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261:1328-1330, 1993
19. Balasa B, Krahl T, Patstone G, Lee J, Tisch R, McDevitt HO, Sarvetnick N: CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 159:4620-4627, 1997
20. Markees TG, Serreze DV, Phillips NE, Sorli CH, Gordon EJ, Shultz LD, Noelle RJ, Woda BA, Greiner DL, Mordes JP, Rossini AA: NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes 48:967-974, 1999
21. Molano RD, Berney T, Li H, Cattan P, Pileggi A, Vizzardelli C, Kenyon NS, Ricordi C, Burkly LC, Inverardi L: Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation. Diabetes 50:270-276, 2001
22. Li H, Kaufman CL, Ildstad ST: Allogeneic chimerism induces donor-specific tolerance to simultaneous islet allografts in nonobese diabetic mice. Surgery 118:192-197, 1995
23. Seung E, Iwakoshi N, Woda BA, Markees TG, Mordes JP, Rossini AA, Greiner DL: Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 95:2175-2182, 2000
24. Guo Z, Mital D, Shen J, Chong AS, Tian Y, Foster P, Sankary H, McChesney L, Jensik SC, Williams JW: Immunosuppression preventing concordant xenogeneic islet graft rejection is not sufficient to prevent recurrence of autoimmune diabetes in nonobese diabetic mice. Transplantation 65:1310-1314, 1998
25. Stegall MD, Loberman Z, Ostrowska A, Coulombe M, Gill RG: Autoimmune destruction of islet grafts in the NOD mouse is resistant to 15-deoxyspergualin but sensitive to anti-CD4 antibody. J Surg Res 64:156-160, 1996
26. Berney T, Molano RD, Cattan P, Pileggi A, Vizzardelli C, Oliver R, Ricordi C, Inverardi L: Endotoxin-mediated delayed islet graft function is associated with increased intra-islet cytokine production and islet cell apoptosis. Transplantation 71:125-132, 2001
27. Read S, Mauze S, Asseman C, Bean A, Coffman R, Powrie F: CD38(+) CD45RB(low) CD4(+) T cells: a population of T cells with immune regulatory activities in vitro. Eur J Immunol 28:3435-3447, 1998
28. low CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 179:589-600, 1994
29. Singh B, Read S, Asseman C, Malmstrom V, Mottet C, Stephens LA, Stepankova R, Tlaskalova H, Powrie F: Control of intestinal inflammation by regulatory T cells. Immunol Rev 182:190-200, 2001
30. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737-742, 1997
31. Kasper LH, Matsuura T, Khan IA: IL-7 stimulates protective immunity in mice against the intracellular pathogen, Toxoplasma gondii. J Immunol 155:4798-4804, 1995
32. Herbelin A, Gombert JM, Lepault F, Bach JF, Chatenoud L: Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. J Immunol 161:2620-2628, 1998
33. Gazda LS, Charlton B, Lafferty KJ: Diabetes results from a late change in the autoimmune response of NOD mice. J Autoimmun 10:261-270, 1997
34. Roach T, Slater S, Koval M, White L, Cahir McFarland ED, Okumura M, Thomas M, Brown E: CD45 regulates Src family member kinase activity associated with macrophage integrin-mediated adhesion. Curr Biol 7:408-417, 1997
35. Shenoi H, Seavitt J, Zheleznyak A, Thomas ML, Brown EJ: Regulation of integrin-mediated T cell adhesion by the transmembrane protein tyrosine phosphatase CD45. J Immunol 162:7120-7127, 1999
36. Atkinson MA, Leiter EH: The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 5:601-604, 1999